PHAR (Pharming Group) Moat Score: 4/10 (As of Jun. 30, 2026)


PHAR Pharming Group PHAR
76 GF Score
Price $13.89
GF Value $14.36
Valuation Fairly Valued
! 1 Warning Sign
View Full Analysis

What is Pharming Group Moat Score?

Pharming Group PHAR +3.73% 76 Moat Score is 4 as of Jun. 30, 2026. GuruFocus rates PHAR with a GF Score™ of 76/100 and a GF Value™ of $14.36 (Fairly Valued). The stock has 1 warning sign investors should review. Among 1,401 Biotechnology companies, Pharming Group ranks better than 88.79% on this metric.

Pharming Group has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

Pharming Group has Narrow Moat: Pharming Group has valuable intellectual property and patents in the biotech sector, providing some competitive edge. However, it lacks strong brand strength and significant regulatory barriers, resulting in a modest moat.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Pharming Group might have Narrow Moat - Discernible but modest moat.

Pharming Group  (NAS:PHAR) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Pharming Group Moat Score Related Terms

PHAR vs VRTX, REGN, ALNY: Moat Score Comparison

For the Biotechnology subindustry, Pharming Group's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Pharming Group Moat Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Pharming Group's Moat Score distribution charts can be found below:

* The bar in red indicates where Pharming Group's Moat Score falls into.


PHAR
76GF Score
Pharming Group PHAR
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
Pharming Group (PHAR) has a Moat Score of 4 as of Jun. 30, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, Pharming Group ranks #157 out of 1401 companies in the Biotechnology industry, placing it in the top 11.2%.
Is Pharming Group's Moat Score too high?
Pharming Group's current Moat Score is 4. The Biotechnology industry median Moat Score is 2.00. Pharming Group's value of 4 is 100% above this industry median. Based on the distribution chart, Pharming Group ranks #157 out of 1401 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Pharming Group has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Pharming Group's Moat Score compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pharming Group ranks #157 out of 1401 companies for Moat Score. This places Pharming Group in the top 11% of its industry — outperforming the majority of peers. The industry median Moat Score is 2.00. Pharming Group's value of 4 is 100% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Biotechnology company?
The median Moat Score among Biotechnology companies is 2.00, based on 1,401 companies in the industry. Companies in the top quartile (top 25%) have a Moat Score significantly above this median, while those in the bottom quartile fall well below. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Pharming Group's current Moat Score of 4 is 100% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. For the Biotechnology industry, the median Moat Score is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pharming Group's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pharming Group stock overvalued right now?
Based on GuruFocus' analysis, Pharming Group (PHAR) is currently considered Fairly Valued. The stock's GF Value™ is $14.36, compared to a current price of $13.89 — trading 3.3% below its estimated fair value. The current Moat Score is 4 and 100% above the Biotechnology industry median of 2.00. Pharming Group's overall GF Score™ is 76/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For Pharming Group (PHAR), the current Moat Score is 4 as of Jun. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Pharming Group (PHAR) Overvalued in 2026?

Based on GuruFocus' analysis, Pharming Group stock appears to be undervalued. The current stock price of $13.89 is trading 3.3% below its estimated GF Value™ of $14.36. GuruFocus considers Pharming Group to be Fairly Valued.

Key valuation signals for PHAR:

  • Moat Score: 4
  • GF Value™: $14.36 vs. price of $13.89 (3.3% below fair value)
  • GF Score™: 76/100 with 1 warning sign
  • Industry Position: 100% above the Biotechnology median (#157 of 1401)

No single metric tells the full story. See the PHAR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Pharming Group Business Description

Address Darwinweg 24, Leiden, ZH, NLD, 2333 CR
Pharming Group is a biotechnology company focused on developing and commercializing therapies for rare and ultra-rare diseases, particularly immunological and genetic conditions with high unmet need. It operates as an integrated company with capabilities across clinical development, manufacturing, regulatory affairs, and commercialization, supported by scientific and operational expertise. It leverages its efficient infrastructure to expand its pipeline and improve patient access to treatment. The Company operates in the United States, Europe, and the rest of the world, with the United States contributing the majority of its revenue.
76GF Score

Get the complete analysis for PHAR

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$13.89
Price
$14.36
GF Value